efficacy of praziquantel against schistosoma mekongi and opisthorchis viverrini a randomized, single-blinded dose-comparison trial吡喹酮的效果对血吸虫湄公和opisthorchis viverrini一项随机、单盲dose-comparison审判.pdfVIP

Efficacy of Praziquantel against Schistosoma mekongi and Opisthorchis viverrini: A Randomized, Single- Blinded Dose-Comparison Trial 1. 2,3. 2,3,4 ´ Leonore Lovis , Tippi K. Mak , Khampheng Phongluxa , Phonepasong Aye Soukhathammavong2,3,4, Youthanavanh Vonghachack2,3,5, Jennifer Keiser3,6, Penelope Vounatsou2,3, 2,3 3,7,8 ¨ 2,3 2,3 4 Marcel Tanner , Christoph Hatz , Jurg Utzinger , Peter Odermatt *, Kongsap Akkhavong ˆ ˆ 1 Laboratory of Parasitology, University of Neuchatel, Neuchatel, Switzerland, 2 Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland, 3 University of Basel, Basel, Switzerland, 4 National Institute of Public Health, Vientiane, Lao People’s Democratic Republic, 5 Parasitology Unit, Faculty of Basic Sciences, University of Health Sciences, Vientiane, Lao People’s Democratic Republic, 6 Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland, 7 Department of Medical Services and Diagnostic, Swiss Tropical and Public Health Institute, Basel, Switzerland, 8 Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland Abstract Background: Schistosomiasis and opisthorchiasis are of public health importance in Southeast Asia. Praziquantel (PZQ) is the drug of choice for morbidity control but few dose comparisons have been made. Methodology: Ninety-three schoolchildren were enrolled in an area of Lao PDR where Schistosoma mekongi